Status:

ENROLLING_BY_INVITATION

124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

Lead Sponsor:

University of Tennessee Graduate School of Medicine

Collaborating Sponsors:

Attralus, Inc.

Conditions:

Lumbar Spinal Stenosis

Carpal Tunnel Syndrome (CTS)

Eligibility:

All Genders

60+ years

Phase:

PHASE2

Brief Summary

This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history of lumbar spinal stenosis and/...

Detailed Description

This is a single center, open label, pilot study using an amyloid-reactive peptide labeled with iodine-124 (124I-evuzamitide) and PET/CT imaging to detect the presence of cardiac and extracardiac amyl...

Eligibility Criteria

Inclusion

  • Must be ≥ 60 years of age.
  • Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
  • Must have a Congo red positive ligamentum flavum or tenosynovial specimen analysis after laminectomy or carpal tunnel release surgery that is visually categorized as either "extensive" amyloid load or "mild/moderate" amyloid load by an experienced reviewer.
  • Those with mild/moderate amyloid load in the connective tissue who also have a history of at least one other orthopedic clinical manifestation, including, but not limited to, carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture, and shoulder/hip/knee arthroplasty.
  • Females must be non-pregnant and non-lactating.

Exclusion

  • Subjects on dialysis.
  • Subjects with a confirmed diagnosis of systemic amyloidosis, other than musculoskeletal tissue.
  • Inability or unwillingness to comply with the study requirements.
  • Subjects taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.
  • Inability to lie still for \~40 minutes on the PET/CT scanner.
  • History of iodine (potassium iodide) allergy.
  • Other reason that would make the subject inappropriate for entry into this study.

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2027

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06907849

Start Date

May 1 2025

End Date

May 1 2027

Last Update

May 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Tennessee Graduate School of Medicine

Knoxville, Tennessee, United States, 37920